Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Hep C Discussion Forum -> Hep C News -> NICE (UK) consults on draft guidance on the drug sofosbuvir (Sovaldi)
Post Info TOPIC: NICE (UK) consults on draft guidance on the drug sofosbuvir (Sovaldi)
Cinnamon Girl


Guru

Status: Offline
Posts: 5629
Date:
NICE (UK) consults on draft guidance on the drug sofosbuvir (Sovaldi)
Permalink  
 

Yes, Isiscat, I`m quite sure the cost is the main issue here, I doubt if they`d be so picky otherwise, and I think the same will apply in the rest of Europe.  I notice the NICE draft guidelines include the following  "Revised cost-effectiveness analyses presented separately for people with and without cirrhosis, with and without HIV-co-infection, and by treatment history."  Our NHS (National Health Service) has already committed to funding for a small number (500) of the most severely affected patients but I`d be surprised if anyone outside those groups in most immediate need will received funding for treatment with Sovaldi.  

Gilead must be aware of this though and at some point surely they`ll have to adjust the cost to comply with market forces especially with some tough competition in the pipeline.

 



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 
Isiscat2011


Guru

Status: Offline
Posts: 1724
Date:
Permalink  
 

One cannot help but wonder if the  "lack of evidence for some subgroups" concern would be as pronounced if Sovaldi was priced lower.  Gilead could actually end up pricing itself out of a good chunk of the market if this trend continues.  

I can envision a scenario where Sovaldi sales are limited to a relatively small group of patients.  Gilead's competitors could then pick up a huge share of the unmet need in the years to come (which means continued warehousing of patients for some time to come). This is how it appears to be playing out in the Euro market and it is possible the same will happen in the US.  

Wouldn't Gilead's profits be greater if it reduced prices on a global scale? Once the market becomes competitive Gilead will need to lower its prices anyway. I'm not sure that playing hard-ball is in Gilead's best interests in the long term. 

In the US will physicians rally to prevent this by prescribing S/L to all despite cost and what effect would that have? Just some random thoughts and questions.  What do others think about all this?



__________________

Diagnosed in 2011, Incivek triple in 2011, tx discontinued, Genotype 1a, CT, VL 7mill, cirrhosis dx in 2012, age 67, waiting for new DAAs.
Cinnamon Girl


Guru

Status: Offline
Posts: 5629
Date:
Permalink  
 

In draft recommendations published on 16th June 2014 healthcare guidance body NICE (the National Institute for Health and Care Excellence) is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C.

Commenting on the draft guidance Professor Carole Longson, Director of the NICE Centre for Health Technology Evaluation, said:

"The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients. However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer. The Committee has therefore requested further information from the manufacturer before it can decide whether sofosbuvir is a cost-effective use of NHS resources."

NICE has not yet issued final guidance to the NHS.  Until then, NHS bodies should make decisions locally on the funding of specific treatments.

Full article and details of draft guidance...

http://www.nice.org.uk/newsroom/pressreleases/NICEOnDraftGuidanceForSofosbuvirSovaldiDrugHepatitisC.jsp



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 
Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.
Hep C Discussion Forum -> Hep C News -> NICE (UK) consults on draft guidance on the drug sofosbuvir (Sovaldi)
Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.